Colonic mucosal prostaglandin e2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer1, 2

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 5, 2001, Pages 447-453

  Krishnan, Koyamangalath ^a   Ruffin, Mack T ^d   Normolle, Daniel ^d   Shureiqi, Imad ^c   Burney, Kimberley ^d   Bailey, Joann ^d   Peters Golden, Marc ^d   Rock, Cheryl L ^b   Boland, C Richard ^b   Brenner, Dean E ^d,e  

^a East Tennessee State University   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; PROSTAGLANDIN E1; PROSTAGLANDIN E2;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COHORT ANALYSIS; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION;

ADULT; AGED; ANALYSIS OF VARIANCE; ASPIRIN; BIOPSY, NEEDLE; CARCINOMA; COLORECTAL NEOPLASMS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034921717     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
2. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
3. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melborne Colorectal Cancer Study
4. Aspirin use and reduced risk of fatal colon cancer
5. Aspirin and the risk of colorectal cancer in women
6. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: Clinical results of a dose-finding study on rectal sulindac administration
7. Clinical and genomic influence of sulindac and rectal mucosa in familial adenomatous polyposis
8. Effects of sulindac on sporadic colorectal adenomatous polyps
9. Treatment of chemically-induced intestinal cancer with indomethacin
10. Effect of indomethacin on intestinal tumor induced in rats by the acetate derivative of dimethylnitrosamine
11. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
12. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
13. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
14. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
15. Aspirin and the role of prostaglandins in colon cancer
16. Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth
17. Early alterations in rat colonic mucosal cyclic nucleotide metabolism and protein kinase activity induced by 1, 2-dimethylhydrazine
18. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis
19. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
20. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
21. Transcriptional activation of cyclooxygenase-2 in Wnt-I transformed mouse mammary epithelial cells
22. Inhibition of NF-κB by sodium salicylate and aspirin
23. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin
24. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
25. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
26. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
27. Effects of sulindac sulfone on cellular proliferation and mucinous differentiation of rectal polyps in patients with familial adenomatous polyposis
28. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
29. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
30. 2 formation and transforming growth factor α expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon
31. Prostaglandin levels in human colorectal mucosa. Effects of sulindac in patients with familial adenomatous polyposis
32. 4 production in human colonic mucosa from cancer patients
33. Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose
34. Prevention of colorectal cancer by colonoscopic polypectomy
35. Tolerability of the synthetic retinoid fenretinide
36. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: Correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis
37. Aspirin, NSAlDs, and colon cancer prevention: Mechanisms?
38. 2 in human colon cancer cells
39. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenetis in polarizing colon cancer cells
40. Cyclooxygenase-2 inhibitors in tumorigenesis (Part 1)
41. Acetylation of prostaglandin endoperoxide synthase with acetylsalicylic acid
42. Effects of nonsteroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities
43. Prostaglandin, H. Synthase: Distinct binding sites for cyclooxygenase and peroxidase substrates
44. Reduced expression of cyclooxygenase-2 proteins in hereditary non-polyposis colorectal cancers relative to sporadic cancers
45. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
46. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
47. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
48. PPAR-δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
49. Mechanistic considerations in chemopreventive drug development
50. Approaches to the development and marketing approval of drugs that prevent cancer
51. Cancer chemoprevention: Progress and promise
52. Colorectal cancer and nonsteroidal anti-inflammatory drugs
53. Cox-2-selective inhibitors: The new super aspirins
54. Lipoxygenase inhibitors as potential cancer chemopreventives